Stocks Health care NVAX
NASDAQ · Health careNovavax Inc (NVAX)
Novavax Inc brought in $411.6M of revenue over the twelve months to September 30, 2026, down 61.3% from a year earlier. It posted a net loss of $76.7M. In fiscal 2025 capital spending exceeded operating cash flow by $250.2M. At September 30, 2026 it held $222.5M in cash against $292.1M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Novavax Inc
- Net worth
- Novavax Inc has a market value (market cap) of $1.8B at the latest share price, and shareholders' equity of -$216.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.1B (+64.7% year on year), with net income of $440.3M. Over the 12 months to September 30, 2026: revenue $411.6M, net loss $76.7M.
- Cash flow
- In fiscal 2025 operations used $244.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Novavax Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Novavax Inc does
Novavax Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker NVAX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.1B | $440.3M | $2.58 | -$250.2M |
| 2024 | $682.2M | -$187.5M | -$1.23 | -$100.3M |
| 2023 | $983.7M | -$545.1M | -$5.41 | -$767.7M |
| 2022 | $2B | -$657.9M | -$8.42 | -$505M |
| 2021 | $1.1B | -$1.7B | -$23.44 | $265.5M |
| 2020 | $475.6M | -$418.3M | -$7.27 | -$97.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where NVAX ranks in Health care
Latest SEC filings
What Novavax Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 3% to $68.3M versus the same quarter last year; diluted EPS -$0.19 versus -$1.25.
- November 5, 2026
- October 29, 2026
- October 16, 2026Passive stake (5% or more) SCHEDULE 13G
- October 16, 2026Activist stake changed SCHEDULE 13D/A
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026
- August 6, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 76% to $56.7M versus the same quarter last year; diluted EPS -$0.32 versus $0.62.
- June 23, 2026
Insider trades
What the people running Novavax Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 20, 2026 | Alton Gregg HDirector | Exercised options | 18,880 | - |
| June 20, 2026 | Mott David MDirector | Exercised options | 18,880 | - |
| June 20, 2026 | Mcglynn Margaret GDirector | Exercised options | 18,880 | - |
| June 20, 2026 | Douglas RichardDirector | Exercised options | 18,880 | - |
| June 20, 2026 | King Rachel K.Director | Exercised options | 18,880 | - |
| June 20, 2026 | Rodgers Richard JDirector | Exercised options | 18,880 | - |
| April 25, 2026 | Newton Charles W.Director | Exercised options | 9,520 | - |
| March 10, 2026 | Shiver John W.Director | Exercised options | 7,947 | - |
Who owns NVAX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Himanshu H. Shah13G, passive with 2 related filers | 6.46% | October 16, 2026 |
| Vanguard Capital Management13G, passive | 5.09% | April 30, 2026 |
Largest institutional holders
Insiders
13 insiders reported holding 958,601 shares in total, about $10.6M at the last price.
| Holder | Shares |
|---|---|
| Jacobs John CPresident and CEO, Director | 225,680 |
| O'Hara ElaineEVP, Chief Strategy Officer | 134,642 |
| Kelly James PatrickEVP, CFO and Treasurer | 130,599 |
| Casey Mark JEVP, Chief Legal Officer | 90,067 |
| Mott David MDirector | 79,770 |
| Douglas RichardDirector | 73,220 |
| Alton Gregg HDirector | 47,685 |
| Rodgers Richard JDirector | 47,370 |
| Mcglynn Margaret GDirector | 44,468 |
| King Rachel K.Director | 44,070 |
Questions about NVAX
What does Novavax Inc do?
Novavax Inc is a company in the Health care sector, listed on NASDAQ as NVAX. Its shares trade on NASDAQ under the ticker NVAX.
What is Novavax Inc's net worth?
Novavax Inc has a market value (market cap) of $1.8B at the latest share price, and shareholders' equity of -$216.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Novavax Inc profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $76.7M on revenue of $411.6M.
How much revenue does Novavax Inc make?
Over the twelve months to September 30, 2026 Novavax Inc reported revenue of $411.6M. That is 61.3% less than a year earlier.
When did Novavax Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Novavax Inc's next earnings report?
Novavax Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare NVAX with
Follow NVAX
Get an email when Novavax Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Novavax Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.